DEXAMETHASONE 3.3 mg/ml, solution for injection
4.1 Therapeutic indications
For use in certain endocrine and non-endocrine disorders responsive to corticosteroid therapy.
Systemic administration: DEXAMETHASONE 3.3 mg/ml, solution for injection is recommended for systemic administration by intravenous or intramuscular injection when oral therapy is not feasible or desirable in the following conditions.
Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice, but synthetic analogues may be used with mineralocorticoids where applicable and, in infancy, mineralocorticoid supplementation is particularly important).
DEXAMETHASONE 3.3 mg/ml, solution for injection may be used in the treatment of non-endocrine corticosteroid- responsive conditions, including:
Allergy and anaphylaxis: Angioneurotic oedema and anaphylaxis.
Gastro-intestinal: Crohn's disease and ulcerative colitis.
Infection (with appropriate chemotherapy): Miliary tuberculosis and endotoxic shock.
Neurological disorders: Raised intracranial pressure secondary to cerebral tumours and infantile spasms.
Respiratory: Bronchial asthma and aspiration pneumonitis.
Skin disorders: Toxic epidermal necrolysis.
Shock: Adjunctive treatment where high pharmacological doses are needed. Treatment is an adjunct to, and not a substitute for, specific and supportive measures the patient may require. DEXAMETHASONE 3.3 mg/ml, solution for injection has been shown to be beneficial when used in the early treatment of shock, but it may not influence overall survival.
DEXAMETHASONE 3.3 mg/ml, solution for injection is suitable for intra-articular or soft-tissue injection as adjunctive therapy for short-term administration in:
Soft-tissue disorders such as carpal tunnel syndrome and tenosynovitis.
Intra-articular disorders such as rheumatoid arthritis and osteoarthritis with an inflammatory component.
DEXAMETHASONE 3.3 mg/ml, solution for injection may be injected intralesionally in selected skin disorders such as cystic acne vulgaris, localised lichen simplex, and keloids.
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC (www.medicines.org.uk/emc/). Medthority offers the whole library of SPC documents from eMC.
Medthority will not be held liable for explicit or implicit errors, or missing data.
Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).